Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) has entered a research partnership with Yale University and the Yale Cardiovascular Research Group (YCRG) in regard to its aortic valve science technology.
The aim of this partnership is to further study the various ways and mechanisms hemodynamic function after transcatheter aortic valve replacement in patients with severe aortic stenosis can be impacted by product design.
YRCG’s research team is led by Dr Alexandra Lansky, MD, director of the YCRG, Professor of Medicine at Yale University of Medicine.
Advancing valve science
Anteris CEO Wayne Paterson said, “This partnership is a testament of Anteris’ commitment to continue to advance valve science through rigorous, scientific research with best-in-class academic centres.”
Yale University and Yale Cardiovascular Research Group have decades of experience in preclinical and clinical cardiovascular research and have been at the forefront of many therapies and health advances over the years.
About Anteris
Anteris Technologies is a structural heart company that delivers clinically superior and durable solutions through better science and better design.
Its focus is developing next-generation technologies that help healthcare professionals reproduce consistent life-changing outcomes for patients.
Anteris’ DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of tomorrow’s younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient’s lifetime.
The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of the DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.